Tri-Valley Sleep Center
Welcome,         Profile    Billing    Logout  
 4 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Prakasam, Gnanagurudasan
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
NCT06366464: A Study of Pitolisant in Patients with Prader-Willi Syndrome

Recruiting
3
134
US
Pitolisant tablet, pitolisant, Placebo tablet, placebo
Harmony Biosciences, LLC
Prader-Willi Syndrome
07/26
07/27
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
SURPASS-PEDS, NCT05260021 / 2021-003612-31: A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

Active, not recruiting
3
99
Europe, US, RoW
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Eli Lilly and Company, Eli Lilly and Company
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
07/24
02/25
OraGrowtH210, NCT04614337 / 2020-000874-92: Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency ( Trial)

Completed
2
82
Europe, US, RoW
LUM-201, rhGH Norditropin® pen (34 µg/kg)
Lumos Pharma, Lumos Pharma
Growth Hormone Deficiency
09/24
09/24
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Active, not recruiting
2
140
Europe, US, RoW
Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo
Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.
Recent Onset type1 Diabetes
04/24
04/26
NCT04604093: Effect of the FreeStyle Libre 2 Flash Glucose Monitoring System on Hyperglycemia in People With T2 Diabetes

Completed
N/A
358
US
SMBG Meter, FreeStyle Libre 2 System
Abbott Diabetes Care
Diabetes Mellitus
02/23
03/23
COACH, NCT03340831: Continuous Monitoring and Control of Hypoglycemia

Recruiting
N/A
1388
US
Continuous Glucose Monitoring (CGM)
DexCom, Inc.
Diabetes
12/23
12/23
NCT02748018: Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

Active, not recruiting
N/A
280
Europe, Canada, US, RoW
670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
Medtronic Diabetes
Type 1 Diabetes
03/25
06/25
NCT05224258: Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

Completed
N/A
240
Canada, US, RoW
MiniMed 780G System
Medtronic Diabetes
Type 1 Diabetes
06/24
06/24
Warner, Megan
NCT06366464: A Study of Pitolisant in Patients with Prader-Willi Syndrome

Recruiting
3
134
US
Pitolisant tablet, pitolisant, Placebo tablet, placebo
Harmony Biosciences, LLC
Prader-Willi Syndrome
07/26
07/27

Download Options